Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CF33-hNIS-antiPDL1 in Metastatic Triple Negative Breast Cancer
NCT05081492Phase 1Active, not recruiting
- Sponsor
- City of Hope
- Start
- Oct 2021
- Primary completion
- Mar 2027
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CF33-hNIS-anti-PD-L1 in triple-negative breast cancer (TNBC), sponsored by City of Hope. Primary endpoint: Incidence of adverse events at 30 days. Started Oct 2021; status: active, not recruiting.
02
Drugs
CF33-hNIS-anti-PD-L1
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05081492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05081492.